Every one of those 1 sits in a single category, clinical-trial. Insider Monkey is most often covered alongside CyPath Lung, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Insider Monkey appears in 1 tracked Biotech story from September 5, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Insider Monkey
Every one of those 1 sits in a single category, clinical-trial. Insider Monkey is most often covered alongside CyPath Lung, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Insider Monkey appears in 1 tracked Biotech story from September 5, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Insider Monkey. Shared-story counts are live from our verified record — not editorial picks.
bioAffinity is leveraging strong clinical data from CyPath Lung, including 92% sensitivity and 99% negative predictive value, to move into post-treatment surveillance. The expansion could broaden the diagnostic's target population beyond initial pulmonary nodule assessment.
Insider Monkey is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.